RE:RE:Concerns to consider
Agree with juansito. This is a risky penny play (as most of penny stocks are) However:
1 ICO has nothing to do with the price of Immune Pharma. In pas two years Immune went from 6$ to 1$, but ICo didn't move.
The reason you see their price moving together this time, it's because ico licensed to Immune the bertilimumab ,so, Ico will receive royalties if trial is succesfull, as you can see from recent Immune news.
https://www.businesswire.com/news/h 2ome/20170804005457/en/Immune-Pharmaceuticals-Issues-Letter-Shareholders
2. Cash will last till h2 2018. Hopefully this will force Andrew Rae to either seek partership or to merge with Immune, in both cases it should be positive for ico. Andrew holds a chunk of ico shares and really concerned about dilution. He could have done a reverse split and dilution many times over in the past, but didn't , (unike most of tsx Ventue companies.....) Inisder info: https://apps.cnbc.com/view.asp?country=US&uid=stocks/ownership&symbol=ico-v&country=CA
3. A small bio company will never complete all phase 1 - 2-3 trials. You are correct. You should see this as a small mining exploration company, once something good is discovered, then company price shoots up or get bought out, in either case, sha